{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T10:10:31Z","timestamp":1755598231731,"version":"3.40.5"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Polypoidal choroidal vasculopathy (PCV) with hemorrhagic complications is at higher risk for breakthrough vitreous hemorrhage (VH). This study aimed to evaluate the clinical features and outcomes of breakthrough VH secondary to PCV. Data of patients receiving pars plana vitrectomy for breakthrough VH secondary to PCV (VH group) were evaluated retrospectively and compared statistically to data of age and sex-matched PCV patients without breakthrough VH (control group). Among PCV patients, 36 eyes with breakthrough VH and 62 eyes without VH were included. Compared with baseline, best corrected visual acuity (BCVA) was worse in the VH group (<jats:italic>P<\/jats:italic> &lt; 0.001), and improved postoperatively (P &lt; 0.001). Percentages of pigmented epithelial detachment (PED), hemorrhagic PED, massive subretinal hemorrhage, hemorrhagic retinal detachment (RD), and hemorrhagic choroidal detachment (CD) (P = 0.007) were higher in the VH group (<jats:italic>P<\/jats:italic> &lt; 0.001). Incidence of choroidal vascular hyperpermeability (<jats:italic>P<\/jats:italic> &lt; 0.001), massive subretinal hemorrhage (<jats:italic>P<\/jats:italic> = 0.001), hemorrhagic retinal detachment (<jats:italic>P<\/jats:italic> = 0.001) and hemorrhagic type PCV (<jats:italic>P<\/jats:italic> = 0.001) was higher in patients with pachychoroid PCV, while fibrovascular type had lower incidence (<jats:italic>P<\/jats:italic> &lt; 0.001). Better initial BCVA (<jats:italic>P<\/jats:italic> &lt; 0.001), higher frequency of anti-VEGF treatment (<jats:italic>P<\/jats:italic> = 0.009), and previous photodynamic therapy (<jats:italic>P<\/jats:italic> = 0.017) showed better visual outcomes. Breakthrough VH risk is higher in PCV patients with massive subretinal hemorrhage, hemorrhagic PED and hemorrhagic RD. BCVA and hemorrhagic complications improve significantly postoperatively. Higher frequency of anti-VEGF treatment and previous photodynamic therapy are associated with better visual prognosis in PCV patients with breakthrough VH.<\/jats:p>","DOI":"10.1371\/journal.pone.0279778","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T19:02:14Z","timestamp":1672426934000},"page":"e0279778","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical features and outcomes of breakthrough vitreous hemorrhage secondary to polypoidal choroidal vasculopathy"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6550-5064","authenticated-orcid":true,"given":"Meng-Syuan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4997-3562","authenticated-orcid":true,"given":"Chui-Lien","family":"Tsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,12,30]]},"reference":[{"issue":"Suppl 1","key":"pone.0279778.ref001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0b013e31823f992a","article-title":"Idiopathic polypoidal choroidal vasculopathy (IPCV). 1990","volume":"32","author":"LA Yannuzzi","year":"2012","journal-title":"Retina"},{"issue":"8","key":"pone.0279778.ref002","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/IAE.0b013e3182953df4","article-title":"Pachychoroid pigment epitheliopathy","volume":"33","author":"DJ Warrow","year":"2013","journal-title":"Retina"},{"issue":"1","key":"pone.0279778.ref003","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.survophthal.2003.10.007","article-title":"Polypoidal choroidal vasculopathy","volume":"49","author":"AP Ciardella","year":"2004","journal-title":"Surv Ophthalmol"},{"issue":"6","key":"pone.0279778.ref004","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/archopht.1996.01100130685008","article-title":"Indocyanine green-guided laser photocoagulation of focal spots at the edge of plaques of choroidal neovascularization","volume":"114","author":"DR Guyer","year":"1996","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"pone.0279778.ref005","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00006982-199805000-00021","article-title":"Diode laser photocoagulation in idiopathic polypoidal choroidal vasculopathy","volume":"18","author":"F Gomez-Ulla","year":"1998","journal-title":"Retina"},{"issue":"8","key":"pone.0279778.ref006","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","volume":"32","author":"A Koh","year":"2012","journal-title":"Retina"},{"issue":"1","key":"pone.0279778.ref007","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00417-008-0926-0","article-title":"Resolving the clinical acuity categories \"hand motion\" and \"counting fingers\" using the Freiburg Visual Acuity Test (FrACT)","volume":"247","author":"C Lange","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"pone.0279778.ref008","first-page":"639","article-title":"Polypoidal choroidal vasculopathy: natural history","volume":"133","author":"M Uyama","year":"2002","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"pone.0279778.ref009","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0039-6257(87)90104-4","article-title":"Vitreous hemorrhage secondary to age-related macular degeneration","volume":"32","author":"JM Googe","year":"1987","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"pone.0279778.ref010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/archopht.121.1.91","article-title":"Pathogenesis of the vitreous cloud emanating from subretinal hemorrhage","volume":"121","author":"H Lincoff","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"pone.0279778.ref011","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1038\/s41598-018-28938-1","article-title":"Risk factors for breakthrough vitreous hemorrhage after intravitreal anti-VEGF injection in age-related macular degeneration with submacular hemorrhage","volume":"8","author":"YI Shin","year":"2018","journal-title":"Sci Rep"},{"issue":"8","key":"pone.0279778.ref012","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/IAE.0000000000003098","article-title":"The Incidence, Characteristics, Management, Prognosis, and Classification of Breakthrough Vitreous Hemorrhage Secondary to Polypoidal Choroidal Vasculopathy","volume":"41","author":"XY Zhao","year":"2021","journal-title":"Retina"},{"issue":"1","key":"pone.0279778.ref013","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ophtha.2007.02.031","article-title":"One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients","volume":"115","author":"F Gomi","year":"2008","journal-title":"Ophthalmology"},{"issue":"3","key":"pone.0279778.ref014","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/01.iae.0000233647.78726.46","article-title":"Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy","volume":"27","author":"Y Hirami","year":"2007","journal-title":"Retina"},{"issue":"9","key":"pone.0279778.ref015","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1097\/IAE.0b013e318214d01e","article-title":"Efficacy of combined photodynamic therapy and intravitreal bevacizumab injection versus photodynamic therapy alone in polypoidal choroidal vasculopathy","volume":"31","author":"SJ Kim","year":"2011","journal-title":"Retina"},{"issue":"4","key":"pone.0279778.ref016","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ajo.2008.05.025","article-title":"Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy","volume":"146","author":"Y Kurashige","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"pone.0279778.ref017","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000076844","article-title":"Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula","volume":"218","author":"SC Lee","year":"2004","journal-title":"Ophthalmologica"},{"issue":"9","key":"pone.0279778.ref018","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","article-title":"Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial","volume":"138","author":"TH Lim","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"pone.0279778.ref019","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12886-020-01419-8","article-title":"Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy","volume":"20","author":"WK Ngo","year":"2020","journal-title":"BMC Ophthalmol"},{"issue":"8","key":"pone.0279778.ref020","doi-asserted-by":"crossref","first-page":"e765","DOI":"10.1111\/aos.13130","article-title":"Three-year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy","volume":"94","author":"T Sakai","year":"2016","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"pone.0279778.ref021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2012.06.027","article-title":"Two-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy","volume":"155","author":"A Yamashita","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"pone.0279778.ref022","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/1120672119871886","article-title":"Initial treatment for polypoidal choroidal vasculopathy: Ranibizumab combined with photodynamic therapy or fixed-dosing aflibercept monotherapy","volume":"30","author":"A Yoneda","year":"2020","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"pone.0279778.ref023","article-title":"Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up","volume":"154","author":"YA Lee","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"pone.0279778.ref024","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1097\/IAE.0000000000001817","article-title":"Disease Activity after Development of Large Subretinal Hemorrhage in Polypoidal Choroidal Vasculopathy","volume":"38","author":"J Baek","year":"2018","journal-title":"Retina"},{"issue":"2","key":"pone.0279778.ref025","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000027400","article-title":"Natural history of macular subretinal hemorrhage in age-related macular degeneration","volume":"213","author":"A Scupola","year":"1999","journal-title":"Ophthalmologica"},{"issue":"4","key":"pone.0279778.ref026","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1111\/j.1755-3768.2009.01850.x","article-title":"Predictable signs of benign course of polypoidal choroidal vasculopathy: based upon the long-term observation of non-treated eyes","volume":"88","author":"A Okubo","year":"2010","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"pone.0279778.ref027","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/0002-9394(82)90301-4","article-title":"Experimental subretinal hemorrhage in rabbits","volume":"94","author":"H Glatt","year":"1982","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"pone.0279778.ref028","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00006982-199111020-00011","article-title":"Tissue plasminogen activator treatment of experimental subretinal hemorrhage","volume":"11","author":"MW Johnson","year":"1991","journal-title":"Retina"},{"issue":"5","key":"pone.0279778.ref029","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/archopht.1991.01080050139046","article-title":"Fibrin directs early retinal damage after experimental subretinal hemorrhage","volume":"109","author":"CA Toth","year":"1991","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"pone.0279778.ref030","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/S0161-6420(99)90399-8","article-title":"Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement","volume":"106","author":"AS Hassan","year":"1999","journal-title":"Ophthalmology"},{"issue":"5","key":"pone.0279778.ref031","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1089\/jop.2010.0066","article-title":"Intravitreal tissue plasminogen activator and pneumatic displacement of submacular hemorrhage","volume":"26","author":"YH Kung","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"pone.0279778.ref032","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0002-9394(99)00474-2","article-title":"Vitreous hemorrhage after intravitreal tissue plasminogen activator (t-PA) and pneumatic displacement of submacular hemorrhage","volume":"129","author":"GT Kokame","year":"2000","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"pone.0279778.ref033","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/01.iae.0000231544.43093.40","article-title":"Pneumatic displacement of submacular hemorrhage: safety, efficacy, and patient selection","volume":"27","author":"M Gopalakrishan","year":"2007","journal-title":"Retina"},{"issue":"12","key":"pone.0279778.ref034","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00417-018-4143-1","article-title":"Morphologic features of large choroidal vessel layer: age-related macular degeneration, polypoidal choroidal vasculopathy, and central serous chorioretinopathy","volume":"256","author":"J Baek","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"pone.0279778.ref035","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/IAE.0000000000002583","article-title":"Difference between Pachychoroid and Nonpachychoroid Polypoidal Choroidal Vasculopathy and Their Response to Anti-Vascular Endothelial Growth Factor Therapy","volume":"40","author":"YC Chang","year":"2020","journal-title":"Retina"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0279778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T19:02:36Z","timestamp":1672426956000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0279778"}},"subtitle":[],"editor":[{"given":"Sanjoy","family":"Bhattacharya","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":35,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0279778","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2022,12,30]]}}}